Epidemiology of MRSA and current strategies in Europe and Japan

Krämer, Axel; Wagenvoort, Hans; Åhrén, Christina; Daniels-Haardt, I.; Hartemann, Philippe; Kobayashi, Hiro; Kurcz, Andrea; Picazo, Juan J.; Privitera, Gaetano Pierpaolo; Assadian, Ojan

doi:10.3205/dgkh000144

Cited by 6 publications

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era

Karakosta,

Vourli,

Kousouli

et al. 2024

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

From 2019 (pre-COVID-19) to 2022 (COVID-19 years), three tertiary Greek hospitals monitored MDRO bloodstream infection (BSI) and hospital acquisition relying on laboratory data. Surveillance covered carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA), in intensive care units (ICUs) and non-ICUs. Non-ICUs experienced significant increases in CRE, CRAB and VRE during the pandemic. In ICUs, CRE increased in 2021, CRAB in 2020 and 2021, and VRE in 2021 and 2022. KPC predominated among CRE. MDRO BSI and hospital acquisition incidence rates increased, driven by CRE and CRAB.

show abstract

Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era

Karakosta,

Vourli,

Kousouli

et al. 2024

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

A Mathematical Model For Optimal Admission Screening For Methicillin Resistant Staphylococcus aureus In Acute Care Facilities

Simmonds¹

2016

View full text Add to dashboard Cite

Costs and Benefits Associated with the MRSA Search and Destroy Policy in a Hospital in the Region Kennemerland, The Netherlands

et al. 2016

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to analyze the costs and benefits of the MRSA Search and Destroy (S&D) policy between 2008 and 2013 in the Kennemer Gasthuis, a 400 bed teaching hospital in the region Kennemerland, the Netherlands.MethodsA patient registration database was used to retrospectively calculate costs, including screening, isolation, follow-up, contact tracing, cleaning, treatment, deployment of extra healthcare workers, salary for an infection control practitioner (ICP) and service of isolation rooms. The estimated benefits (costs and lives when no MRSA S&D was applied) were based on a varying MRSA prevalence rate (up to 50%).ResultsWhen no MRSA S&D policy was applied, the additional costs and deaths due to MRSA bacteraemia were estimated to be € 1,388,907 and 33 respectively (at a MRSA prevalence rate of 50%). Currently, the total costs were estimated to be € 290,672 (€ 48,445 annually) and a MRSA prevalence rate of 17.3% was considered as break-even point. Between 2008 and 2013, a total of 576 high risk patients were screened for MRSA carriage, of whom 19 (3.3%) were found to be MRSA positive. Forty-nine patients (72.1%) were found unexpectedly.ConclusionsApplication of the MRSA S&D policy saves lives and money, although the high rate of unexpected MRSA cases is alarming.

show abstract

Epidemiology of MRSA and current strategies in Europe and Japan

Cited by 6 publications

References 59 publications

Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era

Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 era

A Mathematical Model For Optimal Admission Screening For Methicillin Resistant Staphylococcus aureus In Acute Care Facilities

Costs and Benefits Associated with the MRSA Search and Destroy Policy in a Hospital in the Region Kennemerland, The Netherlands

Contact Info

Product

Resources

About